Key result
Early ECG screening and beta-blockers remain essential for managing long QT syndrome after syncope.
Why the study?
LQTS has significant mortality and variable clinical course, and the authors aimed to highlight the roles of lifestyle changes alongside pharmacotherapy in its treatment.
Highlights the importance of ECG screening after syncope, genetic testing, and a combination of pharmacotherapy and lifestyle changes in managing pediatric Long QT Syndrome.
Supports ECG screening in pediatric syncope for LQTS; leaves open optimal genetic testing integration with therapy.
Long QT syndrome (LQTS) is a hereditary disease with significant mortality, which might be reduced with appropriate management.This cardiac disorder is regarded as rare, but its prevalence remains unknown.The clinical course of LQTS is variable and syncope is a common first manifestation of LQTS.Therefore in each patient after syncope an ECG should be carried out.However, there is no universal QT value applying to all patients (especially infants and children), because it varies depending on age and sex.Genetic testing can be of great importance for the management of families with LQTS and early identification of patient relatives at risk of developing disease.We aimed to show that a very important part of treatment is not only pharmacotherapy, especially beta-blockers, but change of lifestyle plays a significant role.
No takes yet. Share an insight, caveat, or question.
Zipser et al. (2019) conducted a review in Long QT Syndrome (LQTS). Beta-blockers and lifestyle modifications was evaluated. Long QT syndrome is a potentially fatal but treatable hereditary arrhythmia that requires early ECG screening in patients presenting with syncope, with management relying on beta-blockers and lifestyle modifications.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: